Recent developments in the treatment of advanced bladder cancer

被引：37
作者：
Godwin, James Luke [1 ]
Hoffman-Censits, Jean [1 ]
Plimack, Elizabeth [2 ]
机构：
[1] Thomas Jefferson Univ, Dept Med Oncol, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA
[2] Temple Hlth, Dept Hematol Oncol, Fox Chase Canc Ctr, Philadelphia, PA USA
来源：
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2018年 / 36卷 / 03期
关键词：
Urothelial carcinoma; Bladder cancer; Immunotherapy; Checkpoint inhibitors; Chemotherapy; Clinical trials; Targeted therapy; Platinum ineligible; METASTATIC UROTHELIAL CARCINOMA; PHASE-II TRIAL; SINGLE-ARM; OPEN-LABEL; MULTICENTER; CISPLATIN; THERAPY; PEMBROLIZUMAB; CHEMOTHERAPY; NIVOLUMAB;
D O I：
10.1016/j.urolonc.2017.12.018
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Urothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions. (c) 2018 Elsevier Inc. All rights reserved.
引用
收藏
页码：109 / 114
页数：6
相关论文
共 30 条
  • [1] [Anonymous], EFFICACY SAFETY NIVO
  • [2] [Anonymous], IMVIGOR
  • [3] Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
    Apolo, Andrea B.
    Infante, Jeffrey R.
    Balmanoukian, Ani
    Patel, Manish R.
    Wang, Ding
    Kelly, Karen
    Mega, Anthony E.
    Britten, Carolyn D.
    Ravaud, Alain
    Mita, Alain C.
    Safran, Howard
    Stinchcombe, Thomas E.
    Srdanov, Marko
    Gelb, Arnold B.
    Schlichting, Michael
    Chin, Kevin
    Gulley, James L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2117 - +
  • [4] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
    Balar, Arjun V.
    Galsky, Matthew D.
    Rosenberg, Jonathan E.
    Powles, Thomas
    Petrylak, Daniel P.
    Bellmunt, Joaquim
    Loriot, Yohann
    Necchi, Andrea
    Hoffman-Censits, Jean
    Perez-Gracia, Jose Luis
    Dawson, Nancy A.
    van der Heijden, Michiel S.
    Dreicer, Robert
    Srinivas, Sandy
    Retz, Margitta M.
    Joseph, Richard W.
    Drakaki, Alexandra
    Vaishampayan, Ulka N.
    Sridhar, Srikala S.
    Quinn, David I.
    Duran, Ignacio
    Shaffer, David R.
    Eigl, Bernhard J.
    Grivas, Petros D.
    Yu, Evan Y.
    Li, Shi
    Kadel, Edward E., III
    Boyd, Zachary
    Bourgon, Richard
    Hegde, Priti S.
    Mariathasan, Sanjeev
    Thastrom, AnnChristine
    Abidoye, Oyewale O.
    Fine, Gregg D.
    Bajorin, Dean F.
    [J]. LANCET, 2017, 389 (10064) : 67 - 76
  • [5] Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
    Bellmunt, J.
    de Wit, R.
    Vaughn, D. J.
    Fradet, Y.
    Lee, J. -L.
    Fong, L.
    Vogelzang, N. J.
    Climent, M. A.
    Petrylak, D. P.
    Choueiri, T. K.
    Necchi, A.
    Gerritsen, W.
    Gurney, H.
    Quinn, D. I.
    Culine, S.
    Sternberg, C. N.
    Mai, Y.
    Poehlein, C. H.
    Perini, R. F.
    Bajorin, D. F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1015 - 1026
  • [6] Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
    Boussiotis, Vassiliki A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (18) : 1767 - 1778
  • [7] Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
    Chae, Young Kwang
    Ranganath, Keerthi
    Hammerman, Peter S.
    Vaklavas, Christos
    Mohindra, Nisha
    Kalyan, Aparna
    Matsangou, Maria
    Costa, Ricardo
    Carneiro, Benedito
    Villaflor, Victoria M.
    Cristofanilli, Massimo
    Giles, Francis J.
    [J]. ONCOTARGET, 2017, 8 (09) : 16052 - 16074
  • [8] Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
    Challita-Eid, Pia M.
    Satpayev, Daulet
    Yang, Peng
    An, Zili
    Morrison, Karen
    Shostak, Yuriy
    Raitano, Arthur
    Nadell, Rossana
    Liu, Wendy
    Lortie, Dawn Ratay
    Capo, Linnette
    Verlinsky, Alla
    Leavitt, Monica
    Malik, Faisal
    Avina, Hector
    Guevara, Claudia I.
    Dinh, Nick
    Karki, Sher
    Anand, Banmeet S.
    Pereira, Daniel S.
    Joseph, Ingrid B. J.
    Donate, Fernando
    Morrison, Kendall
    Stover, David R.
    [J]. CANCER RESEARCH, 2016, 76 (10) : 3003 - 3013
  • [9] Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986
    De Santis, Maria
    Bellmunt, Joaquim
    Mead, Graham
    Kerst, J. Martijn
    Leahy, Michael
    Maroto, Pablo
    Gil, Thierry
    Marreaud, Sandrine
    Daugaard, Gedske
    Skoneczna, Iwona
    Collette, Sandra
    Lorent, Julie
    de Wit, Ronald
    Sylvester, Richard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 191 - 199
  • [10] Phase II Trial of Cisplatin, Gemcitabine, and Bevacizumab As First-Line Therapy for Metastatic Urothelial Carcinoma: Hoosier Oncology Group GU 04-75
    Hahn, Noah M.
    Stadler, Walter M.
    Zon, Robin T.
    Waterhouse, David
    Picus, Joel
    Nattam, Sreenivasa
    Johnson, Cynthia S.
    Perkins, Susan M.
    Waddell, Mary Jane
    Sweeney, Christopher J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) : 1525 - 1530
123